BRUCE C. NYDAHL, M.D.; WENDELL H. HALL, M.D., F.A.C.P.
Nafcillin (UNIPEN®) is one of the new penicillinase-resistant semisynthetic penicillins. It can be administered orally or parenterally. In vitro studies have shown it to have high activity against penicillinase-producing staphylococci and other gram-positive cocci, although less than penicillin G against the latter group. Clinical reports on nafcillin have dealt largely with absorption, excretion, and distribution of the drug (1-5) and staphylococcal integumentary infections. A summary of our total experience with nafcillin in 50 cases will be presented. During this study several aspects of staphylococcal disease impressed us as warranting comment, particularly the renal complications. The following cases are reported in
NYDAHL BC, HALL WH. The Treatment of Staphylococcal Infection with Nafcillin with a Discussion of Staphylococcal Nephritis. Ann Intern Med. ;63:27–43. doi: 10.7326/0003-4819-63-1-27
Download citation file:
Published: Ann Intern Med. 1965;63(1):27-43.
Infectious Disease, Nephrology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use